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Background: Because treadmill exercise testing is more representative of daily activity than 
cycle testing, we developed treadmill protocols to be used in various clinical settings as part 
of a two-year, multicenter, chronic obstructive pulmonary disease (COPD) trial evaluating the 
effect of tiotropium on exercise.
Methods: We enrolled 519 COPD patients aged 64.6 ± 8.3 years with a postbronchodilator 
forced expiratory volume in one second (FEV1) of 1.25 ± 0.42 L, 44.3% ± 11.9% predicted. The 
patients performed symptom-limited treadmill tests where work rate (W
.
) was increased linearly 
using speed and grade adjustments every minute. On two subsequent visits, they performed 
constant W
.
 tests to exhaustion at 90% of maximum W
.
 from the incremental test.
Results: Mean incremental test duration was 522 ± 172 seconds (range 20–890), maximum 
work rate 66 ± 34 watts. For the first and second constant W
.
 tests, both at 61 ± 33 watts, mean 
endurance times were 317 ± 61 seconds and 341 ± 184 seconds, respectively. The mean of two 
tests had an intraclass correlation coefficient of 0.85 (P , 0.001). During the second constant 
W
.
 test, 88.2% of subjects stopped exercise because of breathing discomfort; 87.1% for Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) Stage II, 88.5% for GOLD Stage III, 
and 90.2% for GOLD Stage IV .
Conclusion: The symptom-limited incremental and constant work treadmill protocol was well 
tolerated and appeared to be representative of the physiologic limitations of COPD.
Keywords: chronic obstructive pulmonary disease, exercise testing, endurance, tiotropium
Introduction
Patients with chronic obstructive pulmonary disease (COPD) have limited exercise 
capacity due to complex pathophysiology, and evaluation of exercise performance 
at all stages of COPD is important if we are to understand disease progression bet-
ter.1 One approach would be to measure aerobic capacity (V
.
O2 max) periodically. 
However, there has been limited development of maximal incremental protocols 
specific for patients with COPD. Furthermore, maximal incremental exercise testing 
is effort-dependent and not representative of everyday activity. Functional exercise 
tests, such as six-minute walking distance, vary significantly in how they are per-
formed from center to center, despite guidelines.2,3 Six-minute walking distance may 
not reflect maximal ability, because it is self-paced and also may not be sensitive to 
pharmacologic intervention.3,4 Oga et al5 reported that among the different types of 
exercise test, the submaximal constant work rate endurance test was the most sensi-
tive in detecting improvements after bronchodilator therapy. Other investigators have 
successfully used this type of test to elucidate physiologic impairments in COPD.6,7 International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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A similar type of test, the   endurance shuttle walk, was 
tested at approximately 75%, 85%, and 95% of maximum 
intensity and found to be both repeatable and sensitive to 
therapeutic changes.8
Cycle ergometry testing has traditionally been used 
to assess the efficacy of treatments. However, walking is 
less likely to induce quadriceps fatigue and is more often 
limited by breathlessness compared with cycling,9 and 
therefore may better reflect the impact of pharmacologically 
induced changes in lung function on exercise tolerance.10,11 
Computer control enables electronically braked cycle 
exercise to be implemented with a continuous linear 
increase in work rate, but now linear treadmill protocols 
have also been described.12 Furthermore, it has been shown 
that treadmill versus cycle exercise elicits higher levels 
of ventilation and is more likely to be associated with 
oxyhemoglobin desaturation.13 Thus, exercise testing using 
a treadmill may better reflect the activities of daily living 
than cycle ergometry.
In order to overcome some of the problems associated 
with cycle ergometry, we developed symptom-limited, 
incremental, and constant work rate (W
.
 ) protocols using 
a treadmill to measure exercise performance in patients 
with COPD. The maximal incremental treadmill protocol 
was designed with an approximate linear increase in work 
rate with respect to time. We then implemented duplicate 
constant load exercise tests at 80% and 90% of the maxi-
mum work rate achieved in the preceding incremental test. 
The repeatability of these constant load exercise tests 
was evaluated in a small pilot study. The objective was to 
standardize a treadmill protocol that would be acceptable 
to COPD patients with a wide range of disease severity 
and would be suitable for use in diverse clinical settings, 
including an international, multicenter, interventional 
clinical trial called EXACTT (a randomized, double-blind, 
placebo-controlled two-year trial to examine the changes 
in exercise endurance and COPD treated with tiotropium 
once daily).
Tiotropium has been documented to improve constant 
work cycle exercise duration in two six-week trials and to 
improve constant speed treadmill exercise in a six-month trial 
in a pulmonary rehabilitation setting.6,7,14 With the EXACTT 
trial, we are seeking to evaluate whether improvements 
in exercise duration with tiotropium in a relatively broad 
selection of COPD patients could be sustained over two 
years using a COPD-specific novel constant work treadmill 
exercise protocol.
Methods
exercise protocol development
The maximal incremental treadmill exercise protocol was 
developed by increasing the work rate at one-minute intervals, 
with the target being symptom limitation in approximately 
8–12 minutes.15 In order to achieve a near-linear increase 
in work rate, a calculated sequence of speed and grade 
adjustments was developed from basic principles.16,17 We 
incorporated a more gradual work rate incrementation early in 
the test specifically designed for impaired subjects. The speed 
and grade adjustments, shown in Table 1, were standardized 
across subjects to maintain the linearity of the incremental 
protocol, but the actual work rates varied according to body 
weight. The work rates shown as an example in Table 1 
assume a subject weighing 70 kg.
A small feasibility study was performed with 12 COPD 
patients at the UCLA Exercise Physiology Research 
Laboratory. Each subject attended at the same time of day 
on three occasions. On the first visit, they performed an 
incremental treadmill test using the adjustments of speed 
and grade as shown in Table 1. On two subsequent visits, 
they performed constant W
.
 tests to exhaustion either at 80% 
Table  1  speed  and  grade  adjustments  used  in  incremental 
treadmill exercise
Time 
(min)*
Speed 
(mph)
Speed 
(m/sec)
Grade 
(%)
Work 
(watts)**
W1 1 0.45 0 “0”
W2 1 0.45 0 “0”
W3 1 0.45 0 “0”
e0 1 0.45 1 3
e1 1 0.45 2 6
e2 1 0.45 3 9
e3 1 0.45 5 15
e4 1.5 0.67 5 23
e5 1.5 0.67 7 32
e6 2 0.89 7 43
e7 2 0.89 8 49
e8 2.5 1.12 8 61
e9 2.5 1.12 9 69
e10 3 1.34 9 83
e11 3.5 1.56 9 96
e12 4 1.79 9 110
e13 4.5 2.01 9 124
e14 5 2.24 9 138
r1 1 0.45 0 “0”
r2 1 0.45 0 “0”
Notes: * W1–W3 represents a three-minute warm-up period. e0–e14 represents a 
15-minute incremental exercise phase. r1–r2 represents a two-minute cool-down 
period; ** Work rate is calculated based on treadmill speed and grade for a subject 
weighing 70 kg. “0” is notionally “zero watts” for the warm-up and cool-down 
phases.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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or 90% of maximum W
.
 determined from the incremental 
test. During each test, minute ventilation (V
.
E) and heart rate 
( fc) were continuously monitored. Oxygen uptake (V
.
O2) and 
carbon dioxide output (V
.
CO2) were derived from exhaled 
gas analysis using a metabolic measurement system (Vmax; 
VIASYS Healthcare, Yorba Linda, CA). This system was 
calibrated using standard routines prior to each exercise test. 
Subjects received standard encouragement during the tests 
using a novel instrument (Figure 1). At the end of the tests, 
rating of perceived exertion was obtained using the original 
Borg RPE scale,18 and breathlessness was evaluated using a 
100 mm visual analog scale.
For the purpose of endurance testing, a fixed percentage 
of the maximum work rate was applied as a constant work 
rate, and time to exhaustion was measured as the outcome 
of interest. The standard approach to constant work rate 
cycle ergometry has been to initiate the test at 75% or 80% 
maximum work rate.6,7 In the feasibility study, we therefore 
used 80% as a starting point for constant work treadmill 
testing. However, it became apparent that 80% of maximal 
work during a treadmill test resulted in a prolonged exercise 
time beyond the target range in a number of patients. Hence 
the constant work was reset to 90% of maximum work. The 
chosen constant work rate (eg, 80% or 90% of maximum) 
is easily derived by proportional reduction of the final speed 
from the incremental test, leaving the final grade unchanged. 
For example, if one desired 90% of maximum work rate in a 
subject whose maximal incremental treadmill settings were a 
speed of 1.34 m/sec (3 mph) and grade of 9%, then the appro-
priate settings would be a speed of 1.21 m/sec (2.7 mph), ie, 
90% of maximum speed, and the same grade of 9%.
eXACTT protocol
The maximal incremental and 90% constant work rate 
treadmill exercise testing protocols described above were 
incorporated into the design of the EXACTT study, which 
aimed to examine the effects of tiotropium on exercise 
endurance in COPD patients over two years. The goal of 
EXACTT was to recruit over 500 subjects and this has been 
achieved using 61 sites in 11 different countries. EXACTT 
included men and women, aged 40–80 years, with a clinical 
diagnosis of COPD, ratio of the forced expiratory volume in 
When patient shows 
signs of fatigue ask: 
Do you feel about 
ready to stop?
Good. Keep going!
Can you manage 
another 30 seconds?
Good. Keep going!
Stop when you 
need to!
NO
NO
YES
YES
Good. Keep going!
Do you feel about 
ready to stop? 
Good. Keep going! Can you manage 
another 30 seconds? 
Stop when you 
need to! 
Figure 1 eXACTT instrument used to optimize maximal effort during incremental and endurance exercise tests.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the first one second to the forced vital capacity of the lungs 
(FEV1/FVC) , 70% and a smoking history greater than 
10 pack-years. Spirometry was performed in accordance 
with American Thoracic Society/European Respiratory 
Society standards.19,20 Measures of FEV1 and FVC were 
compared with reference values from the Third National 
Health and Nutrition Examination Survey (NHANES III).21 
Patients with pulmonary disease other than COPD, includ-
ing asthma, clinically significant bronchiectasis, interstitial 
lung disease, pleural disease, and previous history of thoracic 
surgery, such as lung resection or lung volume reduction sur-
gery, were excluded. Patients requiring supplemental oxygen 
at rest or during exercise to prevent desaturation (,85%) 
were also excluded. Patients with disorders that could 
impact their ability to participate in exercise testing, such as 
obesity (body mass index .30 kg/m2), and cardiovascular 
or musculoskeletal disease were excluded. Patients were 
allowed to continue taking other prescribed medications, 
including long-acting β-sympathomimetic bronchodilators 
and inhaled corticosteroids, with the same timing and dosage 
throughout the study. The following respiratory medications 
were washed out prior to each clinic visit for exercise 
testing: short-acting theophylline (24 hours), long-acting 
theophylline (48 hours), inhaled corticosteroids (12 hours), 
long-acting inhaled beta-agonists (24 hours), combination 
inhaled corticosteroid-long-acting beta-agonists (24 hours), 
and short-acting beta-agonists (eight hours). At the beginning 
of the EXACTT study, subjects had treadmill exercise testing 
on three visits. At visit 1, they performed the incremental 
protocol. At visits 2 and 3, constant work rate protocols were 
performed at 90% of the initial maximum work rate. Visits 
1, 2, and 3 were separated by seven or 14 days, depending 
on tiotropium use at consent as specified in the protocol. The 
exercise tests on visits 2 and 3 were separated by a minimum 
of three days. The only data captured from these tests were 
for endurance time. Gas exchange measurements were not 
included in the protocol for the EXACTT study. Subjects were 
permitted to use the rails for balance but were requested not 
to hold onto the rails. Standardization was achieved through 
a central training and an interactive DVD/web-based training 
system. Successful completion of training was required for 
all study staff conducting exercise testing. Treadmills were 
calibrated annually according to the procedures described in 
the National Aeronautics and Space Administration manual 
entitled “Procedures for Exercise Laboratories” (http://ston.
jsc.nasa.gov/collections/TRS/_techrep/TM-1998-104826.
pdf). After baseline testing, the subjects are being followed 
for two years with three-monthly measurements of constant 
work rate treadmill exercise endurance time at 90% of the 
initial maximum work rate. This paper presents data from 
the pilot feasibility study, as well as the baseline character-
istics, before randomization, of the subjects recruited into 
the EXACTT study.
statistical analysis
Data were analyzed using the SAS software package (version 
9.2; SAS Institute, Cary, NC). The subject characteristics, 
including endurance times for the incremental tests 
(visit 1) and paired constant W
.
 tests (visits 2 and 3), are 
presented as mean values with standard deviations (SD). The 
reproducibility of exercise tests was assessed by computing 
intraclass correlation coefficient for the mean of two tests.22 
Intraclass correlation scores are based on Shrout and Fleiss 
and present the two-way mixed average.23
Based on two previous tiotropium exercise trials using con-
stant work rate cycle ergometry, the SD of exercise duration 
was assumed to be around 300 seconds.6,7 The difference 
between tiotropium and placebo for the constant work rate 
test was approximately 105 seconds. A total of 173 patients in 
each group would provide 90% power to detect a 105-second 
difference in exercise duration at the 0.025 significance level. 
Given that the primary endpoint might not be normally dis-
tributed, a sample size of 184 in each group would be needed 
using a Wilcoxon (Mann–Whitney) rank-sum test. To ensure 
sufficient power for analyzing the primary endpoint in the 
set of patients treated for at least 48 weeks and assuming a 
discontinuation rate of about 20%, the sample size was set 
at 230 patients per group.
Results
Feasibility study
For the feasibility study, we recruited 12 clinically stable 
COPD patients (nine men, three women), mean age 69.5 ± 7.8 
years, FEV1 1.44 ± 0.38 L (33%–70% of reference). The 
important parameters of their exercise tests are summarized 
in Table 2. The mean incremental test duration approxi-
mated 10 minutes. Plots of V
.
O2 versus time indicated linear 
increases in V
.
O2 during incremental testing, with a mean 
gradient of V
.
O2 versus W
.
 of 10.7 ± 4.3 mL/min/watt, indi-
cating work efficiency similar to that of cycle ergometry.24 
Seven patients demonstrated a V
.
O2 plateau at the end of 
the test, confirming maximal effort. A metabolic threshold 
(V
.
O2θ), above which lactic acid was deduced to have accu-
mulated, was identified in 11/12 subjects by noninvasive gas 
exchange measurements using the method of Beaver et al25 
in conjunction with analysis of the ventilatory equivalents International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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and end-tidal gas tensions for oxygen and carbon dioxide.26 
The V
.
O2θ was compared with the lower limit of normal.27 
Five patients reached a V
.
E max . 85% of their ventilatory 
capacity (as measured by maximum voluntary ventilation 
over 12 seconds) and might thus have been considered to 
be ventilation limited. For the constant W
.
 tests, V
.
O2 max, fc 
max and V
.
E max were higher, with 90% of W
.
 max rather than 
80%, suggesting that the 90% tests were more successful 
at eliciting a true maximal effort (see Table 2). Ratings of 
perceived exertion and breathlessness were similar for the 
incremental and 90% constant work rate tests. Comparing 
80% and 90% tests, coefficients of variation were endurance 
time 16% versus 17%, V
.
O2 max 10% versus 7%, V
.
CO2 max 
10% versus 8%, fc max 6% versus 3%, and V
.
E max 10% versus 
7%. We concluded from these data that the symptom-limited 
incremental treadmill protocol was well tolerated in patients 
with moderate to very severe COPD. Constant W
.
 tests at 90% 
compared with 80% of W
.
 max resulted in a narrower range 
of endurance times and slightly more repeatable physiologic 
measures. However, the 90% tests always followed the 80% 
tests and so there could have been a sequence effect related 
to familiarization with the exercise protocol.
eXACTT study
subjects
Five hundred nineteen patients were randomized into the 
EXACTT study. The demographics and baseline characteristics of 
these subjects are shown in Table 3. There were 401 men and 
118 women with a mean age of 64.6 ± 8.3 years. The mean 
postbronchodilator FEV1 was 44.3% ± 11.9% of predicted. 
According to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) criteria,28 187 patients had moderate (Stage II) 
COPD, 261 had severe (Stage III) COPD, and 71 patients had 
very severe (Stage IV) COPD. The cohort comprised 34.3% 
current smokers and 65.7% former smokers. On average, they 
had smoked for approximately 51.7 ± 27.7 pack years and 
Table 2 Physiologic data from the pilot feasibility study
Parameter Maximal incremental Constant 80% W
.
 max Constant 90% W
.
 max
Visit 1 Visit 2 Visit 3 Visit 2 Visit 3
Time (seconds) 575 (170) 599 (221) 713 (267) 308 (180) 388 (235)
speed (mph) 2.7 (1.0) 2.2 (0.7) 2.2 (0.7) 2.6 (0.8) 2.6 (0.8)
grade (%) 8.2 (1.6) 8.4 (1.4) 8.4 (1.4) 8.1 (1.5) 8.1 (1.5)
W
.
 (watts) 80 (38) 67 (29) 68 (30) 77 (34) 77 (34)
V
.
O2 max (L/min) 1.34 (0.36) 1.28 (0.35) 1.26 (0.37) 1.41 (0.39) 1.40 (0.43)
V
.
O2 max (% reference) 86 (23) 81 (22) 79 (21) 96 (29) 95 (26)
V
.
O2 max (mL/kg/min) 16.7 (4.2) 15.2 (2.9) 14.9 (2.9) 17.6 (4.3) 17.3 (3.9)
V
.
O2/W
.
 (mL/min/watt) 10.7 (4.3) – – – –
V
.
O2θ (L/min) 0.98 (0.17) – – – –
V
.
O2 (6’–3’) (L/min) – 0.05 (0.08) 1.22 (0.41) 0.13 (0.03) 0.12 (0.08)
V
.
CO2 max (L/min) 1.29 (0.40) 1.22 (0.37) 1.22 (0.41) 1.41 (0.51) 1.35 (0.50)
fc max (/min) 119 (17) 113 (14) 112 (13) 122 (17) 119 (13)
fc max (% reference) 80 (13) 75 (11) 74 (11) 81 (10) 79 (8)
V
.
E max (L/min) 43.7 (11.6) 44.2 (13.2) 45.1 (15.4) 46.8 (14.6) 48.4 (17.4)
V
.
E max/MVV (%) 77 (18) 68 (16) 69 (20) 85 (11) 87 (11)
rPe (Borg 6–20) 15.0 (1.8) – – 14.8 (2.1) 15.1 (2.2)
Dyspnea (VAs 0–100) 50 (20) – – 52 (28) 58 (28)
Note: Values are mean (± standard deviation).
Abbreviations: W
.
, work rate; V
.
O2, oxygen uptake; V
.
O2(6’–3’), change in oxygen uptake between the third and sixth minutes of the test (oxygen uptake drift); V
. 
CO2 , carbon 
dioxide output, fc, heart rate; V
.
E, minute ventilation; MVV, maximum voluntary ventilation; rPe, rating of perceived exertion (on original Borg 6–20 scale); VAs, visual analog 
scale (with terminal anchors of “not at all breathless” and “extremely breathless”). 
Table 3 eXACTT patient demographics and baseline   character-
istics
Parameter Result
Men/women, n 401/118
Age (years) 64.6 (8.3)
Body mass index (kg/m2) 26.4 (4.2)
Current/former smokers 178/341
smoking history (pack-years) 51.7 (27.7)
Duration of COPD (years) 8.8 (6.7)
Prebronchodilator FeV1 (L) 1.08 (0.40)
Prebronchodilator FeV1 (% predicted) 38.2 (11.2)
Postbronchodilator FeV1 (L) 1.25 (0.42)
Postbronchodilator FeV1 (% predicted) 44.3 (11.9)
FVC (L) 2.93 (0.72)
FeV1/FVC (%) 50.7 (13.5)
Concurrent LABA, n (%) 300 (57.8)
Concurrent ICs, n (%) 311 (59.9)
Note: Values are mean (sD) unless otherwise stated. 
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  FeV1,  forced 
expiratory volume in one second; FVC, forced vital capacity; LABA, long-acting 
β-agonist; ICs, inhaled corticosteroid.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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were known to have COPD for 8.7 ± 6.6 years. The number of 
patients with evaluable data at visits 1, 2, and 3 were 512, 459, 
and 463, respectively.
Incremental test
The mean ± SD exercise endurance time for the incremental 
exercise test at visit 1 was 522 ± 172 seconds. Individual 
exercise endurance times ranged from 20 seconds to 
890 seconds (see Figure 2). The maximum work rate was 
66.3 ± 33.9 watts. Values of endurance time and work 
rate for different stages of COPD severity are shown in 
Table 4.
Constant work rate tests
The mean ± SD and median endurance times for the constant 
W
.
 tests were 316 ± 200 and 260 seconds, respectively, on 
visit 2 compared with 341 ± 184 and 290 seconds on visit 
3 (see Figures 3 and 4). The range of values for visit 2 was 
42–1096 seconds and for visit 3 or visit 3r (with work rate 
adjustment) the range was 42–900 seconds. The constant 
work rates for the two visits were 61.0 ± 32.4 and 60.4 ± 32.6 
watts. Values of endurance time and work rate for the different 
stages of COPD severity are shown in Table 4. Data were 
available for identical constant W
.
 tests at visits 2 and 3 in 
470 subjects. The target endurance time for the constant 
work rate tests was 120–900 seconds. If endurance time 
was .900 seconds, the work rate was increased, whereas 
if endurance time was ,120 seconds, the work rate was 
reduced. Increases or reductions in the constant work rate 
were obtained using speed and grade from either the previ-
ous or next stage of the standard protocol. Constant work 
rate was modified 56 times in 52 subjects, being reduced 32 
times in 31 subjects and increased 24 times in 21 subjects. 
There was good repeatability of endurance times between 
two identical tests (n = 470), with an intraclass correlation 
coefficient of 0.85 (P , 0.001) for the mean of two tests 
(see Figure 5).
Locus of symptom limitation
The reasons for stopping exercise during the constant W
.
 
exercise tests are shown in Table 5. At visit 2, 402 (85.4%) 
of the patients stopped exercise due to breathlessness 
with or without leg fatigue compared with 416 (88.3%) at 
visit 3. There was a high degree of consistency (79.0%) in 
the reasons given for stopping exercise, with few patients 
switching reasons between these two visits.
safety
At the time of this analysis, 422 (81%) of subjects have been 
retained in the EXACTT trial. Overall, 50 subjects   experienced 
76 adverse events. Events which occurred in .1% of patients 
were COPD exacerbation (seven patients) and cough (five 
patients). Two patients experienced serious adverse events, 
ie, COPD exacerbation and hypotension. The hypotension 
occurred shortly after exercise testing, but no other serious 
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Figure 2 Distribution of patients by endurance time for the incremental exercise tests at visit 1 (n = 512). The mean ± standard deviation exercise endurance time was 
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events were associated with exercise testing. Electrocardiograms 
were monitored and there were only two reports of premature 
ventricular contractions and one report of self-limiting ven-
tricular tachycardia. Nonserious advents which occurred on 
more than one occasion during exercise testing were vertigo 
(three patients), dizziness or lightheadedness (four patients), 
and abdominal pain (two patients). There have been no reports 
of accidental falls or problems with instability.
Discussion
The purpose of the present study was to develop incremental 
and constant work rate treadmill exercise testing protocols 
and then to implement them in the international, multicenter 
EXACTT study. The primary outcome measure in EXACTT 
will be endurance time at 90% of maximum work rate. All 
patients enrolled were able to complete the incremental and 
constant work exercise tests, and no subjects were lost to 
follow-up because of technical difficulties with test admin-
istration. Determination of exercise endurance time does not 
depend upon gas exchange measurements, thus simplifying 
the test protocols and allowing them to be performed quickly 
and cost effectively.
The incremental treadmill test was designed based on 
calculated increases in speed and grade to obtain a linear 
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Figure 3 Distribution of endurance time for constant W
.
  exercise tests at visit 2 (n = 459). The mean ± standard deviation and median endurance times were 316 ± 200 and 
260 seconds, respectively.
Table 4 Duration and work rate from the eXACTT incremental and constant work rate exercise tests
GOLD stage Visit 1 Visit 2 Visit 3
Time sec W
.
 max watts Time sec W
.
 con watts Time sec W
.
 con watts
stage II: moderate 
(n = 185)
557 (168) 74 (34) 340 (209) 69 (34) 361 (178) 68 (34)
stage III: severe 
(n = 260)
517 (179) 65 (34) 305 (197) 60 (32) 321 (180) 59 (33)
stage IV: very severe 
(n = 71)
443 (128) 50 (22) 295 (182) 45 (21) 362 (207) 45 (22)
All stages 
(n = 516)
522 (172) 66 (34) 317 (201) 61 (33) 341 (184) 61 (33)
Note: Values are means (± standard deviations).
Abbreviations: Visit 1, incremental work rate test; visit 2, constant work rate test at 90% of maximum work rate from visit 1; visit 3, repeat identical constant work rate 
test; time, endurance time in seconds; W
.
 max, maximum work rate for the incremental exercise test at visit 1; W
.
 con, constant work rate for the exercise tests at visits 
2 and 3; gOLD, global initiative for chronic obstructive lung disease. International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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increase in V
.
O2  suitable for patients with COPD. Plots of V
.
O2 
versus time from the subjects in the pilot study confirm that 
this objective was achieved. The data also show a mean incre-
mental test time of approximately 10 minutes, with most tests 
falling within the target range of 8–12 minutes. In the pilot 
study, subjects attained 80% of predicted maximum heart 
rate, and V
.
O2 max was 86% of that predicted for sedentary 
individuals.16 Furthermore, 7/12 subjects had evidence of a 
plateau in V
.
O2 despite further increase in W
.
, suggesting a 
true maximal test. Work efficiency was, on average, similar 
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Figure 5 Comparison of endurance times for constant W
.
 exercise tests at visits 2 and 3. The means of the two tests had an intraclass correlation coefficient of 0.85 (P , 0.001).
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to what would be expected with incremental cycle ergom-
etry.24 Only 5/12 subjects exhibited ventilatory limitation 
(V
.
E max > 85% of maximum voluntary ventilation measured 
directly over 12 seconds prior to exercise testing). This is a 
typical finding in COPD patients where there can be other 
reasons for exercise limitation. In summary, this incremen-
tal W
. 
 protocol, specific for patients with COPD, is novel, 
feasible, and well tolerated by patients with COPD ranging 
from moderate to very severe by GOLD criteria.28
The EXACTT study will evaluate the long-term effect 
of tiotropium on exercise tolerance in patients with COPD 
over two years. The rationale for this study is based on the 
results of several short-term clinical trials in patients with 
COPD demonstrating improvement with tiotropium 18 µg 
once daily on exercise duration using different types of 
exercise protocol.6,7,14,29 For example, two six-week protocols 
evaluated constant work cycle ergometry,6,7 one 12-week 
study examined the incremental shuttle walk test,29 and a 
fourth study examined constant speed treadmill testing as an 
outcome in patients receiving tiotropium or matching placebo 
in combination with pulmonary rehabilitation.14
Commonly used exercise tests have several limitations. 
Standard protocols for cardiopulmonary exercise testing, 
such as the Bruce protocol, are generally too demanding for 
COPD patients and were designed for other purposes.30 The 
six-minute walking test has gained acceptance in a variety of 
chronic pulmonary diseases, but is subject to preset behav-
iors and has been shown to be administered inconsistently.3 
This type of functional exercise test exhibits large within-
subject variability from day to day, and therefore requires 
considerable attention to standardization.2 For example, it has 
been shown to be nonresponsive to bronchodilator therapy 
despite improvement in FEV1, and also in shuttle walking 
performance.31 The endurance shuttle walk test may be more 
responsive than the six-minute walking test,31 but it could 
also have limitations given the need to move back and forth 
on a corridor and to perform sharp turns which might cause 
instability. Revill et al8 noted the energy expenditure will 
likely be higher in the shuttle walk compared with a treadmill 
test due to the turning of corners. Furthermore, a 20-minute 
ceiling effect has been recognized with the shuttle test which 
could pose problems in the evaluation of higher functioning 
individuals.32 A potential benefit of constant work treadmill 
testing is that there may not be a ceiling effect in higher 
functioning subjects.
Constant work cycle ergometry has an accepted, stan-
dardized methodology and has proven to be responsive 
to pharmacologic interventions.6,7,33 However, cycling 
is not usually a habitual activity for COPD patients, and 
involves different muscle recruitment than walking. Cycle 
ergometry may mask true treatment effects that improve 
ventilatory mechanics due to cessation of work from leg 
fatigue. Pepin et al11 evaluated changes in endurance time 
during cycling and walking (endurance shuttle test) in 17 
patients with COPD with placebo and ipratropium. Endur-
ance time increased by a mean of 51 seconds with cycling 
and by a mean of 164 seconds with walking. Quadriceps 
twitch force was reduced with cycling, but not with walking 
and, furthermore, there was a shift in the locus of symptom 
limitation towards dyspnea rather than leg fatigue with 
the walking test. These observations suggest that walking 
endurance tests minimize the contribution of leg fatigue to 
exercise limitation, and should therefore be more sensitive 
for detecting improvements in dyspnea related to alterations 
in ventilatory mechanics. These issues highlight the need for 
an endurance walking test with a standardized protocol that 
is applicable in COPD patients. Acceptance of a constant 
work rate endurance test for the evaluation of pharmacologic 
interventions will certainly require wider experience of such 
Table 5 reason for stopping the constant work rate exercise 
test at randomization in eXACTT (visit 3)
GOLD stage Reason for 
stopping
Number Percentage 
within stage
stage II: moderate 
(n = 187)
Breathing 
discomfort
107 57.2
Leg discomfort 23 12.3
Both 56 29.9
neither 1 0.5
Any breathing 163 87.1
stage III: severe 
(n = 261)
Breathing 
discomfort
170 65.1
Leg discomfort 26 10.0
Both 61 23.4
neither 4 1.5
Any breathing 231 88.5
stage IV: very severe  
(n = 71)
Breathing 
discomfort
45 63.4
Leg discomfort 6 0.1
Both 19 26.8
neither 1 1.4
Any breathing 64 90.2
All stages 
(n = 519)
Breathing 
discomfort
322 62.0
Leg discomfort 55 10.6
Both 136 26.2
neither 6 1.1
Any breathing 458 88.2
Notes: Values are absolute numbers in each category followed by the percentage of 
all patients with the same stage of chronic obstructive pulmonary disease severity. 
“Any  breathing”  refers  to  the  combined  number  of  patients  in  the  “breathing 
discomfort” and “both” categories.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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testing and comparison with functional exercise tests, such 
as the six-minute walking test.
An optimal test duration of 8–12 minutes is often quoted 
for maximal incremental exercise testing.15 According to 
the power-duration curve, there is a nonlinear relationship 
between intensity of a task and the duration for which the 
task can be performed. Thus, a too low intensity results in 
prolonged exercise duration, masking ventilatory limitation 
and limiting ability to detect true intervention effects. By 
contrast, a too high intensity results in insufficient data for 
interpretation. A recent study of COPD patients (Stages III 
and IV) performing incremental cycle ergometry suggests 
an optimal test duration of approximately 5–9 minutes, as 
compared with 8–12 minutes for normal subjects.34
The duration of the second treadmill constant W
.
 tests 
at 90% of W
.
 max on visit 3 of the EXACTT study was 
340 seconds. Notably, there were several tests of prolonged 
duration (one being almost 20 minutes). An obvious reason 
for such prolonged endurance is that the initial incremental 
test underestimated true W
.
 max, and thus 90% of this value 
represented a relatively low intensity. Such prolonged tests 
need to be avoided in the setting of clinical trials where endur-
ance time is an important clinical endpoint. For this reason, 
for 21 subjects in EXACTT whose endurance time exceeded 
15 minutes, we adjusted the constant W
.
 and repeated the test. 
For the 470 subjects performing identical constant W
.
 tests 
at visits 2 and 3, there was good repeatability of endurance 
times between the two tests (intraclass correlation 0.85). 
We considered this degree of variation to be an acceptable 
baseline for the EXACTT clinical trial.
This study has several limitations. Firstly, it is recognized 
that the feasibility study included a low number of patients. 
However, it appeared that patients tolerated the protocol and 
it was feasible to institute. Secondly, in the EXACTT study, 
we excluded subjects who were obese, but recognize that a 
significant proportion of COPD patients do have a body mass 
index .30. The EXACTT protocol might not be so easily 
tolerated in heavier subjects, and this will have to be evalu-
ated separately. Thirdly, we deliberately chose to increment 
the work rate slowly at the beginning of the incremental 
exercise tests. This was to improve subject comfort during 
testing. We acknowledge, however, that this might have 
led to an underestimation of peak power, especially in sub-
jects with lower functional capacity. Had this phenomenon 
occurred, our selection of 90% of maximum work rate for 
the endurance tests would be even more appropriate. Another 
recognized limitation of the study is the exclusion of patients 
with an FEV1 . 65%. However, we believe that our subject 
population is representative of the type of patient seen in 
clinical practice. Finally, regarding differences in exercise 
duration between repeated visits, the possibility of a learning 
effect cannot be excluded.
We have sought to minimize subjective perception of leg 
fatigue as the factor limiting exercise so as to have a stimulus 
that would maximize the potential to demonstrate true 
improvements in ventilatory mechanics. A large international 
trial involving constant work cycle ergometry suggested that 
leg fatigue (either alone or in combination with breathless-
ness) was responsible for 53%–66% of patients reason for 
stopping exercise.7 The treadmill protocol we developed 
resulted in 88% of subjects reporting breathing discomfort 
alone or in conjunction with leg fatigue as the locus of symp-
tom limitation. This feature renders the EXACTT protocol 
particularly suitable for eliciting potential improvements in 
exercise capacity where there is limitation by dyspnea.
Conclusions
In summary, the maximal incremental treadmill exercise test 
protocols we have developed were well tolerated by patients 
with moderate to very severe COPD. We believe that treadmill 
testing is more representative of the physiologic limitations 
of the COPD patient than cycle ergometry, particularly given 
that our data show that breathlessness is more likely to be the 
limiting factor in treadmill exercise tests. Additionally, the 
test protocols we have developed may be performed easily in 
a variety of clinical settings. They are being further evaluated 
as part of a multinational clinical trial.
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